Maxalt

Rizatriptan, the active ingredient in Maxalt, is a Triptan presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults. GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxalt is a Triptan indicated for the acute management of migraine, acting on the serotonergic pathway to relieve headache symptoms. Migraine (acute): provides rapid relief of headache pain and associated nausea, photophobia, and phonophobia.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Taste disturbance: altered or unpleasant taste sensation. - Dizziness: light‑headed feeling or vertigo. - Fatigue: feeling unusually tired. - Nausea: mild stomach upset. - Dry mouth: reduced salivation. - Tingling or numbness: peripheral sensory changes.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Chest pain or tightness: may indicate cardiac ischemia. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hypertension: sudden increase in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Ischemic events: stroke or myocardial infarction.

Before prescribing Maxalt, clinicians should evaluate patient history and comorbid conditions. - Cardiovascular disease: avoid in uncontrolled hypertension, coronary artery disease, or history of stroke. - Concomitant serotonergic drugs: assess risk of serotonin syndrome. - Other triptans or ergot alkaloids: do not use together due to additive vasoconstriction. - Pregnancy and lactation: consult a physician; safety not established. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Rizatriptan can interact with several medication classes, requiring careful review.

Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin syndrome. - Other triptans: additive vasoconstrictive effects. - Ergot alkaloids: increased risk of vasospasm.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or other serotonergic agents: monitor for serotonin syndrome. - Antihypertensives: may enhance blood‑pressure lowering effects. - CYP3A4 inhibitors (e.g., ketoconazole): may raise rizatriptan plasma concentrations.